相关实验视频

Updated: Jul 25, 2025

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

肺高血压在ANCA相关的血管炎:一个回顾性分析

Misbah Baqir¹, Narayana Sarma Singam², Hilary DuBrock³

¹Pulmonary Medicine Department, Mayo Clinic Rochester MN USA. baqir.misbah@mayo.edu.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG

|June 29, 2023

概括

抗中性粒细胞抗体 (ANCA) 相关血管炎 (AAV) 的肺高血压 (PH) 通常是由多种因素引起的,包括心脏和肺部疾病. 这种情况显著增加了AAV患者的死亡风险.

科学领域:

心脏病学心脏病学
类风湿病学类风湿病学
肺部病理学肺部病理学

背景情况:

肺高血压 (PH) 在患有抗中性粒细胞抗体 (ANCA) 相关血管炎 (AAV) 的患者中尚不清楚.
在AAV中调查PH是非常重要的,因为它可能对患者的治疗结果产生影响.

研究的目的:

为了确定在AAV患者中PH的原因.
确定与PH的AAV患者死亡率相关的风险因素.
分析PH在AAV中的预后影响.

主要方法:

在1997年至2015年期间诊断出PH的97名AAV患者的回顾性审查.
将PH患者与没有PH的558名AAV患者进行比较.
用于PH检测的心声学;从电子健康记录中抽取的数据.

主要成果:

在AAV中的PH通常是多因素的,最常见的是左心病和慢性肺病.
老年,男性性别,吸烟史和脏参与与PH存在有关.
在AAV患者中,PH诊断与死亡率增加有关 (HR 3.15),平均存活时间为25.9个月.

结论:

在AAV中的PH通常是多因素的,经常涉及左心脏病.
在AAV中存在PH表明预后不佳.
高血压,老年,吸烟和病是AAV死亡的独立风险因素.

更多相关视频

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...